Please assess the completion status of the following clinical trial:

Trial Title: Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men over 18 years of age with a life expectancy ≥ 10 years~  -.Unilateral adenocarcinoma of the prostate accurately located and confirmed as unilateral using high resolution biopsy strategies based on current best practice, such as multi- parametric MRI based strategies or template-based biopsy procedures.~* Clinical stage T1c or T2a,~* Gleason Score ≤ 6, based on high-resolution biopsy strategies~* 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1 -2 positive cancer cores with ≥ 50 % cancer involvement in any one core or a PSA density ≥ 0.15 ng/mL/cm3.~* PSA ≤ 10 ng/mL~* If the patient is sexually active with women who are capable of getting pregnant, he and/or his partner should use an effective form of birth control to prevent getting pregnant during a period of 90 days after the VTP procedure.~* Signed Informed Consent Form~Exclusion Criteria:~GENERAL EXCLUSION CRITERIA :~* Unwillingness to accept the treatment;~* Any previous prostatic interventions where the internal urinary sphincter may have been damaged, including trans-urethral resection of the prostate (TURP) for benign prostatic hypertrophy.~* Participation in another clinical study involving an investigational product within 1 month before study entry;~* Inability to understand the informed consent document, to give consent voluntarily or to complete the study tasks, especially inability to understand and fulfill the health-related QOL questionnaire;~* Subjects in custody and or residing in a nursing home or rehabilitation facility;~* Biopsy proven locally advanced or metastatic prostate cancer.~SURGERY AND OTHER TREATMENT-RELATED CONDITIONS OF EXCLUSION~* Any condition or history of illness or surgery that in the opinion of the investigator might affect the conduct and results of the study or pose additional risks to the subject or any medical condition that precludes the administration of a general anaesthetic or invasive procedures.~* Hypersensitivity to the active substance or to the excipient (mannitol)~* Current or prior treatment for prostate cancer.~* Patients who have been diagnosed with cholestasis.~* Current exacerbation of rectal inflammatory bowel disease.~* Anticoagulant medicinal products and those that decrease platelet aggregation (e.g. acetylsalicylic acid) should be stopped at least 10 days before the procedure with TOOKAD. Medicinal products that prevent or reduce platelet aggregation should not be started for at least 3 days after the procedure.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TOOKAD VTP (Type: EXPERIMENTAL): TOOKAD is administered as part of focal VTP under general anaesthetic. TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.

Based on this trial design, predict the completion outcome and termination type (if applicable).